Summary
Tryptophan (Trp) is an indispensable amino acid required for biosynthesis of proteins, serotonin and niacin. Indoleamine 2,3-dioxygenase (IDO) is induced by infections, viruses, lipopolysaccharides, or interferons (IFNs) and this results in significant catabolism of Trp along the kynurenine (Kyn) pathway. Intracellular growth of Toxoplasma gondii and Chlamydia psittaci in human fibroblasts in vitro is inhibited by IFN-gamma and this inhibition is negated by extra Trp in the medium. Similarly, growth of a number of human cell lines in vitro is inhibited by IFN-gamma and addition of extra Trp restores growth. Thus, in some in vitro systems, antiproliferative effects of IFN-gamma are mediated by induced depletion of Trp. We find that cancer patients given Type I or Type II IFNs can induce IDO which results in decreased serum Trp levels (20-50% of pretreatment) and increased urinary metabolites of the Kyn pathway (5 to 500 fold of pretreatment). We speculate that in vivo antineoplastic effects of IFNs and clinical side effects are mediated, at least in part, by a general or localized depletion of Trp.
In view of reported increases of IFNs in autoimmune diseases and our earlier findings of elevated urinary Trp metabolites in autoimmune diseases, it seems likely that systemic or local depletion of Trp occurs in autoimmune diseases and may relate to degeneration, wasting and other symptoms in such diseases. We find high levels of IDO in cells isolated from synovia of arthritic joints.
IFNs are also elevated in human immunodeficiency virus (HIV) patients and increasing IFN levels are associated with a worsening prognosis. We propose that IDO is induced chronically by HIV infection, is further increased by opportunistic infections, and that this chronic loss of Trp initiates mechanisms responsible for the cachexia, dementia, diarrhea and possibly immunosuppression of AIDS patients. In these symptoms, AIDS resembles classical pellagra due to dietary deficiency of Trp and niacin. In preliminary studies, others report low levels of Trp and serotonin, and elevated levels of Kyn and quinolinic acid in AIDS patients. The implications of these data in cancer, autoimmune diseases and AIDS are discussed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bender, D.A., 1987, The relative importance of dietary tryptophan and preformed nicotinic acid and nicotinamide as precursors of nicotinamide nucleotide coenzymes, in: “Progress in Tryptophan and Serotonin Research 1986”, Bender, D.A., Joseph, M.H., Kochen, W., and Steinhart, H.W., eds., de Gruyter, Berlin, pp. 159–164.
Bernton, E.W., Meltzer, M.S., and Holaday, J.W., 1988, Suppression of macrophage activation and T-lymphocyte function in hypoprolactinemic mice, Science, 239: 401–404.
Beutler, B., 1988, The presence of cacheetin/tumor necrosis factor in human disease states, Am. J. Med., 85: 287–288.
Brown, R.R., Borden, E.C., Sondel, P.M., Byrne, G.I., Lee, C.M., Nunnink, J.C., Schiller, J.H., and Lehman, L.K., 1986, Effects of interferons and interleukin-2 on tryptophan metabolism in humans, J. Cell Biochem. Suppl., 10C: 230.
Brown, R.R., Borden, E.C., Sondel, P.M., and Lee, C.M., 1987, Effects of interferons and interleukin-2 on tryptophan metabolism in humans, in: “Progress in Tryptophan and Serotonin Research 1986”, Bender, D.A., Joseph, M.H., Kochen, W., and Steinhart, H.W., eds., de Gruyter, Berlin, pp. 19–26.
Brown, R.R., Lee, C.M., Kohler, P.C., Hank, J.A., Storer, B.E., and Sondel, P.M., 1989, Altered tryptophan metabolism in cancer patients treated with recombinant interleukin-2, Cancer Res., 49: 4941–4944.
Burkes, R.L., Sherrod, A.E., Stewart, M.L., Gill, P.S., Aguilar, S., Taylor, C.R., Krailo, M.D., and Levine, A.M., 1986, Serum beta-2 microglobulin levels in homosexual men with AIDS and with persistent, generalized lymphadenopathy, Cancer, 57: 2190–2192.
Byrne, G.I., Lehmann, L.K., Kirschbaum, J.G., Borden, E.C., Lee, C.M., and Brown, R.R., 1986b, Induction of tryptophan degradation in vitro and in vivo: a gamma interferon-stimulated activity, J. Interferon Res., 6: 389–396.
Byrne, G.I., Lehmann, L.K., and Landry, G.J., 1986a, Induction of tryptophan catabolism is the mechanism for gamma-interferon-mediated inhibition of intracellular Chlamydia psittaci replication in T24 cells, Infect. Immun., 53: 344–351.
Carlin J.M., Borden, E.C., and Byrne, G.I., 1989b, Enhancement of indoleamine 2,3-dioxygenase activity in cancer patients receiving interferon-βser, J. Interferon Res., 9: 167–173.
Carlin, J.M., Borden, E.C., Sondel, P.M., and Byrne, G.I., 1989a, Interferoninduced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes, J. Leukocyte Biol., 45: 29–34.
Carlin, J.M., Ozaki, Y., Byrne, G.I., Brown, R.R., and Borden, E.C., 1989c, Interferons and indoleamine 2, 3-dioxygenase: role in antimicrobial and antitumor effects, Experientia, 45: 535–541.
Cleveland, M.G., Annable, C.R., and Klimpel, G.R., 1988, In vivo and in vitro production of IFN-β and IFN-γ during graft vs. host disease, J. Immunol., 141: 3349–3356.
Datta, S.P., Brown, R.R., Borden, E.C., Sondel, P.M., and Trump, D.L., 1987a, Interferon and interleukin-2 induced changes in tryptophan and neopterin metabolism: possible markers for biologically effective doses, Proc. Am. Assoc. Cancer Res., 28: 338.
Datta, S.P., Brown, R.R., Schiller, J.H., Storer, B.E., and Borden, E.C., 1987b, Neopterin (NP) levels in cancer patients treated with human recombinant interferon (IFN). Abstract, Annual Meeting of the International Soc. for Interferon Research, Washington, D.C, November 2–6.
de la Maza, L.M., and Peterson, E.M., 1988, Dependence on the in vitro antiproliferative activity of recombinant human g-interferon on the concentration of tryptophan in culture media, Cancer Res., 48: 346–350.
Denicoff, K.D., Rubinow, D.R., Papa, M.Z., Simpson, C., Seipp, C.A., Lotze, M.T., Chang, A.E., Rosenstein, D., and Rosenberg, S.A., 1987, The neuropsychiatrie effects of treatment with interleukin-2 and lymphokine-activated killer cells, Ann. Internal. Med., 107: 293–300.
DeStefano, E., Friedman, R.M., Friedman-Kien, A.E., et al., 1982, Acid-labile human leukocyte interferon in homosexual men with Kaposi’s sarcoma and lymphadenopathy, J. Infect. Dis., 146: 451–455.
Eyster, M.E., Goedert, J.J., Poon, M-C., and Preble, O.T., 1983, Acid-labile alpha interferon. A possible preclinical marker for the acquired immunodeficiency syndrome in hemophilia, N. Engl. J. Med., 309: 583–586.
Ferrari, C., Caldara, R., Romussi, M., Rampini, P., Telloli, P., Zaatar, S., and Curtarelli, G., 1978, Prolactin suppression by serotonin antagonists in man: further evidence for serotoninergic control of prolactin secretion, Neuroendocrinology, 25: 319–328.
Finocchiaro, L.M.E., Arzt, E.S., Fernandez-Castelo, S., Criscuolo, M., Finkielman, S., and Nahmod, V.E., 1988, Serotonin and melatonin synthesis in peripheral blood mononuclear cells: stimulation by interferon-gamma as part of an immunomodulatory pathway, J. Interferon Res., 8: 705–716.
Flinn, J.H., Price, J.M., Yess, N., and Brown, R.R., 1964, Excretion of tryptophan metabolites by patients with rheumatoid arthritis, Arthr. Rheumatol., 7: 201–210.
Fuchs, D., and Wachter, H., 1988, Inflammatory joint disease and HIV infection, Brit. Med. J., 297: 422–423.
Goebel, F.D., Erfle, V., Piechowiak, H., Hien, P., Schloz, R., and Hehlmann, R., 1985, The relations of HTLV-III antibodies to neopterin and beta-2-microglobulin in the serum of patients with AIDS or persons at risk, in: “Biochemical and Clinical Aspects of Pteridines”, Vol. 4, Wachter, H., Curtius, H.C., and Pfleiderer, W., eds., de Gruyter, Berlin, pp. 319–333.
Goldstein, D., Sielaff, K.M., Storer, B.E., Brown, R.R., Datta, S.P., Witt, P.L., Teitelbaum, A.P., Smalley, R.V., and Borden, E.C., 1989, Human biological response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-βser, J. Nat. Cancer Inst., 81: 1061–1068.
Grant, I., Atkinson, J.H., Hesselink, J.R., Kennedy, C.J., Richman, D.D., Spector, S.A., and McCutchan, J.A., 1987, Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections, Ann. Int. Med., 107: 828–836.
Green, J.A., and Spruance, S.L., 1984, Acid-labile alpha interferon, New Engl. J. Med., 310: 922–923.
Hansotia, P., Peters, H., Bennet, M., and Brown, R.R., 1969, Chelation therapy in Wegner’s granulomatosis treatment with EDTA, Ann. Otol. Rhinol. Laryngol., 78: 388–402.
Hasegawa, H., Kobayashi, T., and Ichiyama, A., 1988, 2,4-Diamino-6-hydroxypyrimidine (DAHP) induces intestinal disorder in mice: an animal model of serotonin deficiency by inhibition of tetrahydrobiopterin (THBP) synthesis, Biol. Chem. Hoppe-Seyler, 369: 532.
Hayaishi, O., Yoshida, R., Takikawa, O., Yasui, H., 1984, Indoleamine dioxygenase — a possible biological function, in: “Progress in Tryptophan and Serotonin Research”, Schlossberger, H.G., Kochen, W., Linzen, B., and Steinhart, H., eds., de Gruyter, Berlin, pp. 33–42.
Heyes, M.P., Rubinow, D., Lane, C., and Markey, S.P., 1989, Cerebrospinal fluid quinolinic acid concentrations are increased in acquired immune deficiency syndrome, Ann. Neurol., 26: 275–277.
Huber, C., Troppmair, J., Fuchs, D., Hausen, A., Lang, D., Niederwieser, D., Reibnegger, G., Swetly, P., Wachter, H., and Margreiter, R., 1985, Immune response-associated production of neopterin-release from macrophages under control of lymphokines, Transplant Proc., 17: 582–585.
Jackson, J.C., Cross, R.J., Walker, R.F., Markesberry, W.R., Brooks, W.H., and Roszman, T.L., 1985, Influence of serotonin on the immune response, Immunology, 54: 505–512.
Karnovsky, M.L., 1986, Muramyl peptides in mammalian tissues and their effects at the cellular level, Fed. Proc, 45: 2556–2560.
Kull, F.C., Jr., Brent, D.A., Parikh, I., and Cuatrecasas, P., 1987, Chemical identification of a tumor-derived angiogenic factor, Science, 236: 843–845.
Lahdevirta, J., Maury, C.P.J., Teppo, A-M., and Repo, H., 1988, Elevated levels of circulating cachetin/tumor necrosis factor in patients with acquired immunodeficiency syndrome, Am. J. Med., 85: 289–291.
Larsson, M., Hagberg, L., Norkrans, G., and Forsman, A., 1989, Indoleamine deficiency in blood and cerebrospinal fluid from patients with human immunodeficiency virus infection, J. Neurosci. Res., 23: 441–446.
Launay, J-M., Copel, L., Callebert, J., Corvaia, N., Lepage, E., Bricare, F., Saal, F., and Peries, J., 1988, Decreased whole blood 5-hydroxytryptamine (serotonin) in AIDS patients, J. Acquired Immune Defic. Synd., 1: 324–325.
Laurence, J., 1987, Dermatologic manifestations of HIV infection, Infections in Med., Jul/Aug, 241–251.
Leyko, M.A., and Varesio, L., 1989, Role for tryptophan and its metabolites in the activation of macrophage tumor cytotoxicity, FASEB J., 3: A822.
Lloyd, P., Stribling, D., and Pogson, C.I., 1983, Endotoxin and tryptophaninduced hypoglycaemia in rats, Biochem. Pharmacol., 31: 3571–3576.
Maclndoe, J.H., and Turkington, R.W., 1973, Stimulation of human prolactin secretion by intravenous infusion of L-tryptophan, J. Clin. Invest., 52: 1972–1978.
Manda, T., Nishigaki, F., Mor, J., and Shimomura, K., 1988, Important role of serotonin in the antitumor effects of recombinant tumor necrosis factor-a in mice, Cancer Res., 48: 4250–4255.
McDonald, E.M., Mann, A.H., and Thomas, H.C., 1978, Interferons as mediators of psychiatric morbidity, Lancet, 2: 1175–1178.
Melmed, R.N., Taylor, J.M.G., Detels, R., Bozorgmehri, M., and Fahey, J.L., 1989, Serum neopterin changes in HIV-infected subjects: indicator of significant pathology, CD4 T cell changes, and the development of AIDS, J. Acquired Immune Defic, 2: 70–76.
Monaco, F., Fumero, S., Mondino, A., and Mutani, R., 1979, Plasma and cerebrospinal fluid tryptophan in multiple sclerosis and degenerative disdiseases, J. Neurol. Neurosurg. Psych., 42: 640–641.
Moon, R.J., 1971, Tryptophan oxygenase and tryptophan metabolism in endotoxin-poisoned and allopurinol-treated mice, Biochim. Biophys. Acta, 230: 324–348.
Moroni, F., Lombardi, G., Carla, V., Lai, S., Etienne, P., and Nair, N.P.V., 1986, Increase in the content of quinolinic acid in cerebrospinal fluid and frontal cortex of patients with hepatic failure, J. Neurochem., 47: 1667–1671.
Murray, H.W., DePamphilis, J., Schooley, R.T., and Hirsch, M.S., 1988, Circulating interferon gamma in AIDS patients treated with interleukin-2, New Engl. J. Med., 318: 1538–1539.
Navia, B.A., Cho, E-S., Petito, C.K., and Price, R.W., 1986, The AIDS dementia complex: II. Neuropathology, Ann. Neurol., 19: 525–535.
Ozaki, Y., Edelstein, M.P., and Duch, D.S., 1987, The action of interferon and antiinflammatory agents on induction of indoleamine 2, 3-dioxygenase in human peripheral blood monocytes, Biochem. Biophys. Res. Commun., 144: 1147–1153.
Ozaki, Y., Edelstein, M.P., and Duch, D.S., 1988, Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferongamma, Proc. Natl. Acad. Sci. USA, 85: 1242–1246.
Pfefferkorn, E.R., 1984, Interferon-gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan, Proc. Natl. Acad. Sci. USA, 81: 908–912.
Pfefferkorn, E.R., Eckel, M., and Rebhun, S., 1986, Interferon-gamma suppresses the growth of Toxoplasma gondii in human fibroblasts through starvation for tryptophan, Mol. Biochem. Parasitol., 20: 215–224.
Price, J.M., Brown, R.R., Rukavina, J.G., Mendelson, C., and Johnson, S.A.M., 1957, Scleroderma (Acrosclerosis). II. Tryptophan metabolism before and during treatment by chelation (EDTA), J. Invest. Dermatol., 29: 289–298.
Rapoport, M.I., and Beisel, W.R., 1971, Studies of tryptophan metabolism in experimental animals and man during infectious illness, Am. J. Clin. Nutr., 24: 807–814.
Reibnegger, G., Bollbach, R., Fuchs, D., Hausen, A., Judmaier, G., Prior, C., Rotthauwe, H.W., Werner, E.R., and Wachter, H., 1986, A simple index relating clinical activity in Crohn’s disease with T cell activation: hematocrit, frequency of liquid stools and urinary neopterin as parameters, Imnmnobiology, 173: 1–11.
Roberts, J., Schmid, F.A., and Rosenfeld, H.J., 1979, Biologic and antineoplastic effects of enzyme-mediated in vivo depletion of L-glutamine, L-tryptophan, and L-histidine, Cancer Treatment Rep., 63: 1045–1054.
Spampinato, S., Locatelli, V., Cocchi, D., Vicentini, L., Bajusz, S., Ferri, S., and Müller, E.E., 1979, Involvement of brain serotonin in the prolactin-releasing effect of opioid peptides, Endocrinology, 105: 163–170.
Sternberg, E.M., Trial, J., and Parker, C.W., 1986, Effect of serotonin on murine macrophages: suppression of Ia expression by serotonin and its reversal by 5-HT2 serotonergic receptor antagonists, J. Immunol., 137: 276–282.
Sternberg, E.M., Van Woert, M.H., Young, S.N., Magnussen, I., Baker, H., Gauthier, S., and Osterland, C.K., 1980, Development of a sclerodermalike illness during therapy with L-5-hydroxytryptophan and carbidopa, New Engl. J. Med., 303: 782–787.
Takikawa, O., Kuroiwa, T., Yamazaki, F., and Kido, R., 1988, Mechanism of interferon-gamma action; characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity, J. Biol. Chem., 263: 2041–2048.
Takikawa, O., Yoshida, R., Kido, R., and Hayaishi, O., 1986, Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase, J. Biol. Chem., 261: 3648–3653.
Talal, N., 1985, Interleukins, interferon and rheumatic disease, Clin. Rheum. Dis., 11: 633–644.
Tutton, P.J.M., and Barkla, D.H., 1987, Biogenic amines as regulators of the proliferative activity of normal and neoplastic intestinal epithelial cells, Anticancer Res., 7: 1–12.
Vivian, V.M., Brown, R.R., Price, J.M., and Reynolds, M.S., 1966, Some aspects of tryptophan and niacin metabolism in young women consuming a low tryptophan diet supplemented with niacin, J. Nutr., 88: 93–99.
Wachter, H., Fuchs, D., Hausen, A., Huber, C., Knosp, O., Reibnegger, G., and Spira, T., 1983, Elevated urinary neopterin levels in patient’s with the acquired immunodeficiency syndrome (AIDS), Hoppe Seyler’s Z. Physiol. Chem., 364: 1345–1346.
Werner, E.R., Bitterlich, G., Fuchs, D., Hausen, A., Reibnegger, G., Szabo, G., Dierich, M.P. and Wachter, H., 1987, Human macrophages degrade tryptophan upon induction by interferon-gamma, Life Sci., 41: 273–280.
Werner, E.R., Fuchs, D., Hausen, A., Jaeger, H., Reibnegger, G., Werner-Felmayer, G., Dierich, M.P., and Wachter, H., 1988, Tryptophan degradation in patients infected by human immunodeficiency virus, Biol. Chem. Hoppe-Seyler, 369: 337–340.
Werner, E.R., Fuchs, D., Hausen, A., Lutz, H., Reibnegger, G., and Wachter, H., 1985, Interferon-gamma-induced in vitro-excretion of neopterin and 3-hydroxyanthranilic acid by human macrophages, in: “Biochemical and Clinical Aspects of Pteridines”, Vol. 4, Wachter, H., Curtius H.C., and Pfleiderer, W., eds., de Gruyter, Berlin, pp. 473–406.
Wooley, P.V., III, Dion, R.L. and Bono, V.H., Jr., 1974, Effects of tryptophan deprivation on L1210 cells in culture, Cancer Res., 34: 1010–1014.
Yasui, H., Takai, K., Yoshida, Y., and Hayaishi, O., 1986, Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurrence in cancer patients, Proc. Natl. Acad. Sci. USA, 83: 6622–6626.
Yoshida, R., and Hayaishi, O., 1978, Induction of pulmonary indo1eamine 2,3-dioxygenase by intraperitoneal injection of bacterial lipopolysaccharide, Proc. Natl. Acad. Sci. USA, 75: 3998–4001.
Yoshida, R., Imanishi, J., Oku, T., Kishida, T., and Hayaishi, O., 1981, Induction of pulmonary indoleamine 2,3-dioxygenase by interferon, Proc. Natl. Acad. Sci. USA, 78: 129–132.
Yoshida, R., Park, S.W., Yasui, H., and Hayaishi, O., 1988, Tryptophan degradation in transplanted tumor cells undergoing rejection, J. Immunol., 141: 2819–2823.
Yoshida, R., Urade, M., Tokuda, M., and Hayaishi, O., 1979, Induction of indoleamine 2,3-dioxygenase in mouse lung during virus infection, Proc. Natl. Acad. Sci. USA, 76: 4084–4088.
Zolla-Pazner, S., William, D., El-Sadr, W., Marmor, M., and Stahl, R., 1984, Quantitation of β-2-microglobulin and other immune characteristics in a prospective study of men at risk for acquired immune deficiency syndrome, J. Am. Med. Assoc., 251: 2951–2955.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Plenum Press, New York
About this chapter
Cite this chapter
Brown, R.R., Ozaki, Y., Datta, S.P., Borden, E.C., Sondel, P.M., Malone, D.G. (1991). Implications of Interferon-Induced Tryptophan Catabolism in Cancer, Autoimmune Diseases and Aids. In: Schwarcz, R., Young, S.N., Brown, R.R. (eds) Kynurenine and Serotonin Pathways. Advances in Experimental Medicine and Biology, vol 294. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-5952-4_39
Download citation
DOI: https://doi.org/10.1007/978-1-4684-5952-4_39
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-5954-8
Online ISBN: 978-1-4684-5952-4
eBook Packages: Springer Book Archive